Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Immunogenicity and safety of the vaccinia virus LC16m8Δ vector expressing SIV Gag under a strong or moderate promoter in a recombinant BCG prime-recombinant vaccinia virus boost protocol.

Sato H, Jing C, Isshiki M, Matsuo K, Kidokoro M, Takamura S, Zhang X, Ohashi T, Shida H.

Vaccine. 2013 Aug 2;31(35):3549-57. doi: 10.1016/j.vaccine.2013.05.071. Epub 2013 May 31.

PMID:
23731631
2.

Prime-boost vaccination using recombinant Mycobacterium bovis BCG and recombinant vaccinia virus DIs harboring HIV-1 CRF01_AE gag in mice: influence of immunization routes.

Promkhatkaew D, Matsuo K, Pinyosukhee N, Thongdeejaroen W, Leang-Aramgul P, Sawanpanyalert P, Warachit P.

Southeast Asian J Trop Med Public Health. 2009 Mar;40(2):273-81.

PMID:
19323012
3.

Effects of different promoters on the virulence and immunogenicity of a HIV-1 Env-expressing recombinant vaccinia vaccine.

Isshiki M, Zhang X, Sato H, Ohashi T, Inoue M, Shida H.

Vaccine. 2014 Feb 7;32(7):839-45. doi: 10.1016/j.vaccine.2013.12.022. Epub 2013 Dec 24.

PMID:
24370703
4.

Priming with a recombinant pantothenate auxotroph of Mycobacterium bovis BCG and boosting with MVA elicits HIV-1 Gag specific CD8+ T cells.

Chapman R, Shephard E, Stutz H, Douglass N, Sambandamurthy V, Garcia I, Ryffel B, Jacobs W, Williamson AL.

PLoS One. 2012;7(3):e32769. doi: 10.1371/journal.pone.0032769. Epub 2012 Mar 29.

6.

Prime-boost immunization of codon optimized HIV-1 CRF01_AE Gag in BCG with recombinant vaccinia virus elicits MHC class I and II immune responses in mice.

Promkhatkaew D, Pinyosukhee N, Thongdeejaroen W, Teeka J, Wutthinantiwong P, Leangaramgul P, Sawanpanyalert P, Warachit P.

Immunol Invest. 2009;38(8):762-79. doi: 10.3109/08820130903070544.

PMID:
19860587
8.

Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity.

Ami Y, Izumi Y, Matsuo K, Someya K, Kanekiyo M, Horibata S, Yoshino N, Sakai K, Shinohara K, Matsumoto S, Yamada T, Yamazaki S, Yamamoto N, Honda M.

J Virol. 2005 Oct;79(20):12871-9. Erratum in: J Virol. 2006 Oct;80(20):10288.

9.

Immunogenicity of newly constructed attenuated vaccinia strain LC16m8Delta that expresses SIV Gag protein.

Suzuki H, Kidokoro M, Fofana IB, Ohashi T, Okamura T, Matsuo K, Yamamoto N, Shida H.

Vaccine. 2009 Feb 11;27(7):966-71. doi: 10.1016/j.vaccine.2008.12.015. Epub 2009 Jan 7.

PMID:
19135118
10.

Enhanced cellular immune responses to SIV Gag by immunization with influenza and vaccinia virus recombinants.

Nakaya Y, Zheng H, García-Sastre A.

Vaccine. 2003 May 16;21(17-18):2097-106.

PMID:
12706700
12.

Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses.

Cayabyab MJ, Korioth-Schmitz B, Sun Y, Carville A, Balachandran H, Miura A, Carlson KR, Buzby AP, Haynes BF, Jacobs WR, Letvin NL.

J Virol. 2009 Jun;83(11):5505-13. doi: 10.1128/JVI.02544-08. Epub 2009 Mar 18.

13.

Rhesus immune responses to SIV Gag expressed by recombinant BCG vectors are independent from pre-existing mycobacterial immunity.

Korioth-Schmitz B, Perley CC, Sixsmith JD, Click EM, Lee S, Letvin NL, Frothingham R.

Vaccine. 2015 Oct 13;33(42):5715-22. doi: 10.1016/j.vaccine.2015.07.010. Epub 2015 Jul 17.

14.

Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model.

Chege GK, Burgers WA, Stutz H, Meyers AE, Chapman R, Kiravu A, Bunjun R, Shephard EG, Jacobs WR Jr, Rybicki EP, Williamson AL.

J Virol. 2013 May;87(9):5151-60. doi: 10.1128/JVI.03178-12. Epub 2013 Feb 28.

15.

A prime-boost immunisation regimen using recombinant BCG and Pr55(gag) virus-like particle vaccines based on HIV type 1 subtype C successfully elicits Gag-specific responses in baboons.

Chege GK, Thomas R, Shephard EG, Meyers A, Bourn W, Williamson C, Maclean J, Gray CM, Rybicki EP, Williamson AL.

Vaccine. 2009 Jul 30;27(35):4857-66. doi: 10.1016/j.vaccine.2009.05.064. Epub 2009 Jun 9.

PMID:
19520196
16.

Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers.

Pinto AR, Fitzgerald JC, Giles-Davis W, Gao GP, Wilson JM, Ertl HC.

J Immunol. 2003 Dec 15;171(12):6774-9.

17.

Optimizing HIV-1-specific CD8+ T-cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors.

Hopkins R, Bridgeman A, Bourne C, Mbewe-Mvula A, Sadoff JC, Both GW, Joseph J, Fulkerson J, Hanke T.

Eur J Immunol. 2011 Dec;41(12):3542-52. doi: 10.1002/eji.201141962. Epub 2011 Oct 26.

18.

Vaccination with a fusion protein that introduces HIV-1 gag antigen into a multitrimer CD40L construct results in enhanced CD8+ T cell responses and protection from viral challenge by vaccinia-gag.

Gupta S, Termini JM, Raffa FN, Williams CA, Kornbluth RS, Stone GW.

J Virol. 2014 Feb;88(3):1492-501. doi: 10.1128/JVI.02229-13. Epub 2013 Nov 13.

20.

Recombinant Mycobacterium bovis bacillus Calmette-Guérin vectors prime for strong cellular responses to simian immunodeficiency virus gag in rhesus macaques.

Sixsmith JD, Panas MW, Lee S, Gillard GO, White K, Lifton MA, Balachandran H, Mach L, Miller JP, Lavine C, DeMarco CT, Tomaras GD, Gee C, Porcelli SA, Larsen MH, Frothingham R, Schmitz JE, Jacobs WR Jr, Haynes BF, Letvin NL, Korioth-Schmitz B.

Clin Vaccine Immunol. 2014 Oct;21(10):1385-95. doi: 10.1128/CVI.00324-14. Epub 2014 Jul 30.

Supplemental Content

Support Center